The ADJUNCT ONE and TWO trials found similar results in terms of body weight and insulin reduction with the 1.8 mg dose of liraglutide, but with an additional modest decrease in HbA1c, as well as an increase in hypoglycemia and hyperglycemia with ketosis. The gene discussed is INS; the disease is Hyperglycemia.